The #ComboMATCH Study, led by researchers from @StanfordCancer, @MDAndersonNews, & @theNCI, is testing new combinations of anti-cancer drugs, based on characteristics found in patients’ tumors or blood. Learn more: bit.ly/ComboMATCH #PrecisionMedicine

Precision oncology is no longer “next.” It’s becoming the operating system for cancer care. In late 2025, the FDA approved imlunestrant with a liquid-biopsy companion diagnostic for ESR1-mutated breast cancer [1]. Regulators have also now formalized how ctDNA/MRD can support drug development in curative-intent solid tumors [2]. And NCI’s next-gen precision trials ComboMATCH, MyeloMATCH, iMATCH are already underway [3]. 🧬 That shifts the bottleneck from discovery to execution: testing access, turnaround time, reimbursement, and trial matching. The competitive edge won’t come only from better drugs, but from better systems ⚕️📉 The real question for leaders: build genomic infrastructure now or watch outcomes and investment concentrate elsewhere. 🤔 Where is precision oncology still overhyped, and where are health systems still moving dangerously too slowly? [1] [fda.gov/drugs/resources-info…](fda.gov/drugs/resources-info…) ([U.S. Food and Drug Administration][1]) [2] [fda.gov/media/183874/downloa…](fda.gov/media/183874/downloa…) ([U.S. Food and Drug Administration][2]) [3] [cancer.gov/about-nci/organiz…](cancer.gov/about-nci/organiz…) ([Cancer.gov][3]) #PrecisionMedicine #Oncology #LiquidBiopsy #CancerCare #Biotech [1]: fda.gov/drugs/resources-info… "FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated ..." [2]: fda.gov/media/183874/downloa… "Guidance for Industry U.S. Food and Drug Administration" [3]: cancer.gov/about-nci/organiz… "NCI-MATCH NCI National Cancer Institute"

ComboMATCH Clinical Trial Protocol Updates Enhance Patient Care "In January 2026, important updates were added to ComboMATCH’s protocol and informed consent document." dctd.cancer.gov/about/news-e…

Explore this news about the @theNCI and @EAonc ComboMATCH initiative: spkl.io/6014AI1tg

Proud to support @theNCI and @EAonc ComboMATCH initiative. Now with the inclusion of our high-quality blood-based biomarker test, results will continue to help determine trial eligibility for patients who may benefit from the effectiveness of biomarker-targeted cancer treatment.

NOW OPEN @RutgersCancer: “A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2 Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial.” @EugeniaGirda #ClinicalTrial #CancerResearch @RWJBarnabas cinj.org/clinical-trials/fin…

Our October Newsletter edition is available! Read about our #BreastCancer Awareness Features, a special study highlight for ComboMATCH N5, current trials on deck, and more! Check it out: conta.cc/4gQfBhP

Do you have advanced #cancer has become worse following treatment, or advanced cancer for which no standard treatment exists? If so, you may be able to join the #ComboMATCH #PrecisionMedicine study. Learn more: bit.ly/ComboMATCH

Fascinating look at how Dr. Chris Karlovich from @theNCI is leading deep molecular analysis to power next-gen clinical trials. Platforms like iMATCH and ComboMATCH are leveraging technologies like WES, RNA-seq, and ctDNA to bring precision combination therapies.@Phase1_NCCH

Kudos to the #NCI #ComboMATCH team, including Dr. James Ford for their ongoing innovative approach to precision oncology basket trials. New concepts are still welcomed! Fantastic talk by Dr. Ford at the our ERTC Committee @SWOG @SupportingSWOG @eaonc @theNCI @Dr_R_Kurzrock

Led by @GShapiroMDPhD at @DanaFarber, joint Alliance @eaonc @nrgorg @swog ComboMATCH trial EAY191-A3 is enrolling patients with RAS-mutated cancers to test effectiveness of enzyme blockers called kinase inhibitors. Learn more: bit.ly/EAY191-A3 @thenci

Sentara's Molecular Diagnostics Laboratory has been chosen by the National Cancer Institute (NCI) to participate in the ComboMATCH clinical trial, a nationwide precision medicine initiative that tests multi-drug combinations for treating solid tumors. bit.ly/45WPalc

#ComboMATCH Treatment Trial E5, led by @kspencer725 of @Perlmutter_CC and @DocDustyD of @UWCarbone, is a randomized phase 2 study of #sotorasib with or without #panitumumab in advanced #SolidTumors. Learn more here: bit.ly/combomatch-e5 #PrecisionMedicine

For #TrialTuesday, @ArdamanShergil1 @UCCancerCenter leads #ComboMATCH Treatment Trial A6 to compare chemo w/wo binimetinib to shrink tumors in patients with advanced biliary tract cancers in a 2nd line setting. Learn more: bit.ly/cmatch-A6 #PrecisionMedicine @ALLIANCE_org

Do you have advanced #cancer that has become worse following treatment, or advanced cancer for which no standard treatment exists? If so, you may be able to join the #ComboMATCH #PrecisionMedicine study. Learn more: bit.ly/ComboMATCH

The #ComboMATCH Study, led by researchers from @StanfordCancer, @MDAndersonNews, @PennCancer, & @NCItreatment, is testing new combinations of anti-#cancer drugs, based on the characteristics of patients’ tumors. Learn more: bit.ly/ComboMATCH #PrecisionMedicine

In the #ComboMATCH Study, researchers are testing if genetically-matched drug combinations will be more effective than single drugs for certain patients with #cancer. Learn more: bit.ly/ComboMATCH #PrecisionMedicine #ClinicalTrial

ComboMATCH/EAY191-E5 tests how well #sotorasib with or without #panitumumab can treat patients with advanced #SolidTumors. For more information: bit.ly/combomatch-e5 cc: @NCItreatment, @kspencer725, @DocDustyD #PrecisionMedicine

Do you have advanced #cancer has become worse following treatment, or advanced cancer for which no standard treatment exists? If so, you may be able to join the #ComboMATCH #PrecisionMedicine study. Learn more: bit.ly/ComboMATCH

Building on the success of NCI-MATCH, the #ComboMATCH #PrecisionMedicine initiative will test new drug combos for patients whose tumors have specific gene abnormalities, regardless of #cancer type. bit.ly/ComboMATCH cc: @NCItreatment @ALLIANCE_org @COGorg @NRGonc @SWOG